Netanya S Utay1, Douglas W Kitch2, Eunice Yeh2, Carl J Fichtenbaum3, Michael M Lederman4, Jacob D Estes5, Claire Deleage6, Clara Magyar7, Scott D Nelson7, Karen L Klingman8, Barbara Bastow9, Amneris E Luque10, Grace A McComsey4, Daniel C Douek11, Judith S Currier12, Jordan E Lake1. 1. Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas. 2. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio. 4. Case Western Reserve University School of Medicine, Cleveland, Ohio. 5. Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon. 6. AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, Maryland. 7. Department of Pathology and Lab Medicine, University of California -Los Angeles (UCLA), Los Angeles, California. 8. HIV Research Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 9. Social and Scientific Systems, Silver Spring, Maryland. 10. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 11. Vaccine Research Center, National Institutes of Health, Bethesda, Maryland. 12. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Abstract
Background: Fibrosis in lymph nodes may limit CD4+ T-cell recovery, and lymph node and adipose tissue fibrosis may contribute to inflammation and comorbidities despite antiretroviral therapy (ART). We hypothesized that the angiotensin receptor blocker and peroxisome proliferator-activated receptor γ agonist telmisartan would decrease lymph node or adipose tissue fibrosis in treated human immunodeficiency virus type 1 (HIV) infection. Methods: In this 48-week, randomized, controlled trial, adults continued HIV-suppressive ART and received telmisartan or no drug. Collagen I, fibronectin, and phosphorylated SMAD3 (pSMAD3) deposition in lymph nodes, as well as collagen I, collagen VI, and fibronectin deposition in adipose tissue, were quantified by immunohistochemical analysis at weeks 0 and 48. Two-sided rank sum and signed rank tests compared changes over 48 weeks. Results:Forty-four participants enrolled; 35 had paired adipose tissue specimens, and 29 had paired lymph node specimens. The median change overall in the percentage of the area throughout which collagen I was deposited was -2.6 percentage points (P = 0.08) in lymph node specimens and -1.3 percentage points (P = .001) in adipose tissue specimens, with no between-arm differences. In lymph node specimens, pSMAD3 deposition changed by -0.5 percentage points overall (P = .04), with no between-arm differences. Telmisartan attenuated increases in fibronectin deposition (P = .06). In adipose tissue, changes in collagen VI deposition (-1.0 percentage point; P = .001) and fibronectin deposition (-2.4 percentage points; P < .001) were observed, with no between-arm differences. Conclusions: In adults with treated HIV infection, lymph node and adipose tissue fibrosis decreased with continued ART alone, with no additional fibrosis reduction with telmisartan therapy.
RCT Entities:
Background: Fibrosis in lymph nodes may limit CD4+ T-cell recovery, and lymph node and adipose tissue fibrosis may contribute to inflammation and comorbidities despite antiretroviral therapy (ART). We hypothesized that the angiotensin receptor blocker and peroxisome proliferator-activated receptor γ agonist telmisartan would decrease lymph node or adipose tissue fibrosis in treated human immunodeficiency virus type 1 (HIV) infection. Methods: In this 48-week, randomized, controlled trial, adults continued HIV-suppressive ART and received telmisartan or no drug. Collagen I, fibronectin, and phosphorylated SMAD3 (pSMAD3) deposition in lymph nodes, as well as collagen I, collagen VI, and fibronectin deposition in adipose tissue, were quantified by immunohistochemical analysis at weeks 0 and 48. Two-sided rank sum and signed rank tests compared changes over 48 weeks. Results: Forty-four participants enrolled; 35 had paired adipose tissue specimens, and 29 had paired lymph node specimens. The median change overall in the percentage of the area throughout which collagen I was deposited was -2.6 percentage points (P = 0.08) in lymph node specimens and -1.3 percentage points (P = .001) in adipose tissue specimens, with no between-arm differences. In lymph node specimens, pSMAD3 deposition changed by -0.5 percentage points overall (P = .04), with no between-arm differences. Telmisartan attenuated increases in fibronectin deposition (P = .06). In adipose tissue, changes in collagen VI deposition (-1.0 percentage point; P = .001) and fibronectin deposition (-2.4 percentage points; P < .001) were observed, with no between-arm differences. Conclusions: In adults with treated HIV infection, lymph node and adipose tissue fibrosis decreased with continued ART alone, with no additional fibrosis reduction with telmisartan therapy.
Authors: Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker Journal: Proc Natl Acad Sci U S A Date: 2015-02-23 Impact factor: 11.205
Authors: Jordan E Lake; David Wohl; Rebecca Scherzer; Carl Grunfeld; Phyllis C Tien; Stephen Sidney; Judith S Currier Journal: AIDS Care Date: 2011-06-24
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Ming Zeng; Peter J Southern; Cavan S Reilly; Greg J Beilman; Jeffrey G Chipman; Timothy W Schacker; Ashley T Haase Journal: PLoS Pathog Date: 2012-01-05 Impact factor: 6.823
Authors: J E Lake; P Debroy; D Ng; K M Erlandson; L A Kingsley; F J Palella; M J Budoff; W S Post; T T Brown Journal: Eur J Endocrinol Date: 2019-10 Impact factor: 6.664
Authors: Suman Srinivasa; Teressa S Thomas; Meghan N Feldpausch; Gail K Adler; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 5.958
Authors: Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey Journal: Clin Gastroenterol Hepatol Date: 2020-10-16 Impact factor: 11.382
Authors: Neeti Agarwal; Claudia E Ramirez Bustamante; Huaizhu Wu; Reina Armamento-Villareal; Jordan E Lake; Ashok Balasubramanyam; Sean M Hartig Journal: Physiol Rep Date: 2022-05
Authors: Jason V Baker; Julian Wolfson; Gary Collins; Caryn Morse; Frank Rhame; Angelike P Liappis; Stacey Rizza; Zelalem Temesgen; Harry Mystakelis; Steven Deeks; James Neaton; Timothy Schacker; Irini Sereti; Russell P Tracy Journal: AIDS Date: 2021-03-15 Impact factor: 4.632
Authors: Zian H Tseng; Ellen Moffatt; Anthony Kim; Eric Vittinghoff; Phil Ursell; Andrew Connolly; Jeffrey E Olgin; Joseph K Wong; Priscilla Y Hsue Journal: N Engl J Med Date: 2021-06-17 Impact factor: 91.245
Authors: Neeti Agarwal; Dinakar Iyer; Pradip Saha; Aaron R Cox; Yan Xia; Netanya S Utay; Anoma Somasundaram; Ulrich Schubert; Jordan E Lake; Sean M Hartig; Ashok Balasubramanyam Journal: Diabetes Date: 2021-07-07 Impact factor: 9.337
Authors: Thomas A Premeaux; Shireen Javandel; Kalei R J Hosaka; Meredith Greene; Nicholas Therrien; Isabel E Allen; Michael J Corley; Victor G Valcour; Lishomwa C Ndhlovu Journal: Front Immunol Date: 2020-06-30 Impact factor: 7.561